Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre …
B Scheiner, MM Kirstein, F Hucke… - Alimentary …, 2019 - Wiley Online Library
Background Programmed cell death protein‐1‐targeted immunotherapy has shown
promising results in phase II studies of hepatocellular carcinoma. Aim To evaluate safety …
promising results in phase II studies of hepatocellular carcinoma. Aim To evaluate safety …
[引用][C] Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international …
B Scheiner, MM Kirstein, F Hucke… - Alimentary …, 2019 - cir.nii.ac.jp
Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular
carcinoma: efficacy and safety data from an international multicentre real-world cohort | CiNii …
carcinoma: efficacy and safety data from an international multicentre real-world cohort | CiNii …
Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre …
B Scheiner, MM Kirstein, F Hucke… - Alimentary …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Programmed cell death protein-1-targeted immunotherapy has shown
promising results in phase II studies of hepatocellular carcinoma. Aim To evaluate safety …
promising results in phase II studies of hepatocellular carcinoma. Aim To evaluate safety …
Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre …
B Scheiner, P Schwabl, F Waneck… - Alimentary …, 2019 - search.ebscohost.com
Background: Programmed cell death protein‐1‐targeted immunotherapy has shown
promising results in phase II studies of hepatocellular carcinoma. Aim: To evaluate safety …
promising results in phase II studies of hepatocellular carcinoma. Aim: To evaluate safety …
Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre …
B Scheiner, MM Kirstein, F Hucke… - Alimentary …, 2019 - europepmc.org
Background Programmed cell death protein-1-targeted immunotherapy has shown
promising results in phase II studies of hepatocellular carcinoma. Aim To evaluate safety …
promising results in phase II studies of hepatocellular carcinoma. Aim To evaluate safety …
Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre …
B Scheiner, MM Kirstein, F Hucke… - Alimentary …, 2019 - research.uni-luebeck.de
Background: Programmed cell death protein-1-targeted immunotherapy has shown
promising results in phase II studies of hepatocellular carcinoma. Aim: To evaluate safety …
promising results in phase II studies of hepatocellular carcinoma. Aim: To evaluate safety …
[引用][C] programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international …
B Scheiner, M Pinter - Alimentary Pharmacology & Therapeutics, 2019 - Wiley Online Library
Letter: programmed cell death proteinâ•’1 (PDâ•’1)â•’targeted immunotherapy in advanced
hepatocellular carcinoma: Page 1 | 231 LETTERS TO THE EDITORS DOI: 10.1111/apt.15334 …
hepatocellular carcinoma: Page 1 | 231 LETTERS TO THE EDITORS DOI: 10.1111/apt.15334 …
[HTML][HTML] Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international …
B Scheiner, MM Kirstein, F Hucke… - Alimentary …, 2019 - ncbi.nlm.nih.gov
Background Programmed cell death protein‐1‐targeted immunotherapy has shown
promising results in phase II studies of hepatocellular carcinoma. Aim To evaluate safety …
promising results in phase II studies of hepatocellular carcinoma. Aim To evaluate safety …
programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real …
B Scheiner, M Pinter - Alimentary pharmacology & …, 2019 - pubmed.ncbi.nlm.nih.gov
Letter: programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced
hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world …
hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world …
programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre …
B Scheiner, M Pinter - Alimentary Pharmacology & …, 2019 - search.ebscohost.com
Letter: programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced
hepatocellular carcinoma: efficacy and s Page 1 | 231 LETTERS TO THE EDITORS DOI …
hepatocellular carcinoma: efficacy and s Page 1 | 231 LETTERS TO THE EDITORS DOI …